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For Twitter :  
UK RCT shows 1 year of CPAP for OSA in people with type 2 diabetes and macular 








We sought to establish whether CPAP for OSA in people with type 2 diabetes and 
diabetic macular oedema (DME) improved visual acuity.  
 
Methods: 
We randomly assigned 131 eligible patients aged 30 to 85 years from 23 UK centres 
with significant DME causing visual impairment (LogMAR letters identified, ≥ 39 to ≤ 
78, score 0.92 to 0.14) plus severe OSA on screening to either:  usual ophthalmology 
care (n=67) or usual ophthalmology care plus CPAP (n=64) for 12 months. 
Results:   
Mean age of participants was 64 years, 73% male, mean BMI 35.0 kg/m2. Mean 4% 
oxygen desaturation index was 36/hour. There was no significant difference in the 
visual acuity at twelve months between the CPAP group and the control group, mean 
LogMAR (95%CI) 0.33 (0.29, 0.37) vs. 0.31 (0.27, 0.35), p=0.39, and no significant 
correlation between change in LogMAR and average CPAP use.  The median daily 
CPAP use (SD, range) was 3.33 (2.25, 0-7.93) hours at three months, 3.19 (2.54, 0-
8.07) hours at six months and 3.21 (2.7, 0-7.98) hours at twelve months.  
Conclusion: CPAP therapy for OSA did not improve visual acuity in people with type 
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INTRODUCTION 
By 2030 diabetes mellitus is expected to affect 8% of the world’s adult population.1  
The risk of developing diabetic retinopathy (DR) and maculopathy correlates with 
diabetes duration.2  Targeted treatment of glycaemia, hypertension and dyslipidaemia 
is recommended to reduce the risk of DR.3-5 When DR and maculopathy are present, 
ophthalmic treatment options include retinal laser photocoagulation to prevent visual 
loss6, and intravitreal anti-Vascular Endothelial Growth Factor (VEGF) 7 or intraocular 
corticosteroid to improve visual acuity.8 
 
Obstructive Sleep Apnoea (OSA) occurs during sleep with recurrent upper airway 
obstruction, causing apnoea, hypoxia and subsequent arousal with pulse and blood 
pressure rises.9 This sleep fragmentation can cause excessive sleepiness, but may 
be asymptomatic. OSA is commonly associated with obesity and is increasing in 
worldwide prevalence alongside T2DM.10  
 
OSA is particularly prevalent in adults with T2DM; rates vary from 23% to 87%. 11,12   
People with DR and maculopathy have a high OSA prevalence, with 34-54% of 
people with diabetic macular oedema (DME) having OSA on screening sleep 
studies.13,14 Guidelines recommend screening for OSA in people with T2DM; many 
remain undiagnosed.15  
 
Treatment of significant OSA includes weight loss and Continuous Positive Airway 
Pressure (CPAP); a positive air pressure applied via a mask covering the nose and/or 
mouth to splint the pharynx, prevent obstruction and consequent intermittent 
hypoxia.16 CPAP improves daytime sleepiness and quality of life in those with 
moderate to severe OSA and is widely used. There are well documented 
improvements in blood pressure with CPAP.17  Randomised controlled trials of CPAP 
have not shown overall effects on diabetes control or insulin resistance 18-20, nor a 
benefit in cardiovascular risk.21,22. 
 
Hypoxia, oxidative stress and inflammation are proposed mechanisms in the 
development of DR.23  Serum rhodopsin mRNA changes occur in people with OSA,24 
and the retinal nerve fibre layer thickness is significantly reduced, correlating with OSA 
severity.25 Changes can be seen in retinal vasculature, with OSA patients having 
increased retinal venular dilation than controls 26. People with OSA and T2DM have 
significantly higher grades of retinopathy and prevalence of maculopathy than those 
without OSA. 27 A meta-analysis showed OSA to be significantly associated with 
increased risk of diabetic retinopathy28; recently OSA was identified as an independent 
predictor for retinopathy progression.29 One uncontrolled study using CPAP in people 
with OSA and DME showed benefits in visual acuity in high CPAP compliers.30  
 
We hypothesised that treatment of OSA with CPAP would improve diabetic macular 
oedema and thus visual acuity. We performed a randomised controlled trial of CPAP 
in people with DR and impaired vision due to DME and concurrent OSA.  
METHODS 
Study Design and Oversight 
The multicentre Retinopathy and Obstructive Sleep Apnoea (ROSA) Trial was a 12 
month randomised controlled trial conducted between 2012 and 2017 (ISRCTN 
number 95411896). The study had ethical approval (Reference 12/NE/0234); all 
participants gave written informed consent. There were 23 UK recruiting 
Ophthalmology centres; the Newcastle Regional Sleep Service was the Coordinating 
Centre. 
 
Patients and Procedures 
An initial patient identification phase was previously published.14  Patients with severe 
OSA (4% ODI ≥ 20/hour or AHI ≥ 30/hour) were contacted by the Coordinating Centre. 
Eligible patients were those with: best corrected visual acuity (BCVA) ≥ 39 and ≤ 78 
letters in at least one eye (using Early Treatment Diabetic Retinopathy Study protocol 
(ETDRS) at a testing distance of 4 meters), central macular oedema in the visually 
impaired eye(s), and willing to have CPAP. Exclusion criteria were: previous CPAP for 
OSA, significant cataract affecting vision, disability precluding informed consent or 
protocol adherence, excessive sleepiness in any driver (based on raised ESS), 
respiratory failure. The latter two were referred for urgent OSA management.  
 
Randomisation and interventions 
Patients were randomised (1:1) to CPAP or control by a central telephone service 
using computer derived treatment allocation (SealedEnvelopeTM) with minimisation 
for: office blood pressure, OSA severity, HbA1c and visual acuity severity. All 
patients had usual best-practice clinical care for DME during the trial, with ocular 
interventions as clinically indicated, determined by their ophthalmologist. They were 
all provided with written information on optimising sleep hygiene and benefits of 
weight loss to OSA by the research team. In addition to usual care, patients 
randomised to CPAP (Autoset S9, ResMed) were instructed by staff who routinely 
initiate CPAP. Humidification and interface choices were made individually. Patients 
were given written and audio-visual information on CPAP plus telephone support: the 
Coordinating Centre contacted all patients after two, seven and 30 days to help 
manage any CPAP difficulties. Patients could telephone for help, and additional visits 
at the local recruiting centre were arranged as required.  
 
Study measurements 
The primary endpoint of the trial was best corrected visual acuity (BCVA) of the study 
eye (LogMAR with refraction, 4 metre ETDRS) at 12 months. Assessments were 
performed at baseline, three, six and twelve months. Ophthalmological measurements 
were completed by trained individuals blind to the patient’s study group. BCVA was 
performed with ETDRS charts after an assessment for lens status and refraction.31 
Visual acuity was recorded as number of letters identified and equivalent LogMAR 
value. Central 1mm macular thickness was measured through OCT (Spectralis®, 
Topcon 2000 or Cirrus, according to centre). Digital retinal photography took one fovea 
and one disc centred image. The same equipment was used by each site for all 
patients. Retinal photographs were graded by two independent graders using UK 
diabetic eye screening grading definitions (v1.3). If grades conflicted, an arbitration 
review was completed. During the baseline and 12 month assessment, grading of any 
cataract was completed using the LOCS 2 protocol.32 The total number of all ocular 
interventions in 12 months was recorded (antiVEGF therapy, intravitreal 
corticosteroids, focal and grid photocoagulation).  
 
Office blood pressure, weight, height, neck and waist circumference were measured 
plus oxygen saturation via finger probe. Non-fasting cholesterol, HDL, triglycerides, 
and HbA1c were checked at each visit, plus thyroid function at baseline only. Self-
assessed health status measurements were taken at each visit: Short Form 12 (SF-
12)33, Visual Function Questionnaire 25 (VFQ-25)34, short Calgary Sleep Apnea 
Quality of Life Index (Short SAQLI)35 plus the Epworth Sleepiness Scale (ESS).36 
 
Statistical Analysis 
We calculated 90 patients randomised 1:1 would provide 80% power to detect 0.1 
difference in LogMAR with 5% significance, based on pilot data showing mean 
difference in LogMAR score at 6 months between compliers with CPAP and non-
compliers was 0.1 (SD 0.17).30 We allowed extra recruitment for an estimated 5% 
dropout and 15% non-adherence rate based on previous CPAP studies. To enable 
exploratory subset analysis, an increase in numbers of 30% was planned. Recruitment 
took longer than anticipated; 131 completed follow up by trial completion. All analyses 
were intention-to-treat (ITT). All participants with at least one post-randomisation 
assessment of the primary outcome were included in the primary analysis. The primary 
outcome of LogMAR at 12 months was analysed using a mixed-effects model, 
accounting for repeated measures over time. The model includes LogMAR score as a 
response variable. Two sided p-value <0.05 was considered significant. Retinopathy, 
maculopathy and photocoagulation at 12 months was analysed by comparing group 
proportions using Pearson’s Chi-Squared test. We further investigated whether 
adherence to CPAP therapy influenced the primary outcome in different ways. We 
defined ‘high’ and ‘low’ compliers based around the mean total hours of CPAP used 
per night at 6 and 12 months, to give similar sized numbers in each group (thus high 
compliers >=2 hours/night, low <2 hours/night). In addition the patients were divided 
into quartiles based on median daily usage of CPAP and with a comparison of the 
change in LogMAR at 12 months adjusting for the baseline LogMAR between Q2, Q3 
and Q4 versus the reference group Q1. Analyses were undertaken using Stata version 
14.2 (StataCorp, College Station, TX) and validated in SAS 9.4, by independent 




There were 222 patients who met the initial eligibility criteria with severe OSA (Figure 
1). At baseline visit, 131 participants were eligible to be randomised. Two patients 
randomised to control requested CPAP during the study, due to worsening sleepiness. 
Some patients randomised to CPAP had zero adherence. The baseline characteristics 
of the participants are shown in Table 1. They were: 92% white Europeans, 5% Asian, 
3% Black, 1% Egyptian. The distribution of minimisation factors for randomisation 
were well balanced between the two groups.  
 
LogMAR  
There were no significant differences in LogMAR at three, six or twelve months 
between the patients in the CPAP group and the control group, after adjusting for the 
minimisation factors (table 2, figure 2). The mean (SD) change in LogMAR at 12 
months was CPAP -0.02 (0.15) and control -0.04 (0.17). After adjustment for 
baseline CMT, this result remained not statistically significant. There was no 
significant correlation between the change in LogMAR and average CPAP use at 
three, six or twelve months (r=-0.15, p=0.31). The change in LogMAR from baseline 
to six months or from six months to twelve months was not statistically significant in 
either the low and high CPAP compliers group, with paired t-test (figure 3). Further 
division of the CPAP group into quartiles based on median daily usage showed no 
significant change in LogMAR at 12 months in any group, or any suggestion of a 
dose-response relationship (Q1 mean (95% CI) LogMAR 0.34 (0.26,0.42), Q2 0.31 
(0.23, 0.39) p=0.63, Q3 0.37 (0.28,0.45) p=0.64, Q4 0.29 (0.21,0.37) p=0.41). 
 
Central Macular Thickness (CMT) 
There was a significant difference in CMT at 3 months, with the CPAP group having 
increased CMT implying worsening oedema compared to the control group: CPAP 
group mean (95%CI) 339.4 (319.5, 359.3) µm vs. control group 312.6 (296.1, 329.2) 
µm, p= 0.045. At 6 months and 12 months there was no significant difference between 
the two groups: CPAP group 12-month mean (95% CI) 320.4 (298.2, 342.6) µm vs. 
control group 309.2 (286.5, 331.9) µm, p=0.53. 
 
  
Ocular interventions  
There was no statistically significant difference between the mean (SD) number of 
ocular interventions over 12 months in the CPAP group 5.2 (3.6 to 6.8) and the 
control group, 3.6 (2.5 to 4.8), p=0.125.  
 
Progression of DR  
The change of proportion of retinopathy, maculopathy and photocoagulation from the 
baseline to at 12 months was not statistically significant in either group (Table 3).  
 
Self-assessed health status 
There was no significant difference between the groups in the VFQ-25 or the SF-12 
at 3, 6 or 12 months. The Short SAQLI showed a statistically significant difference at 
3 months between the groups implying symptomatic benefit from CPAP (mean 
(95%CI) CPAP 2.3 (2.1,2.5) vs. control 2.8 (2.6,2.9), p=0.003), but no significant 
difference between groups at 6 or 12 months. 
 
ESS 
There was no significant difference in the ESS between groups at 3, 6 or 12 months 
(table 4). High CPAP compliers showed a statistically significant fall of ESS at 3 
months (p=0.02) but no significant fall at 6 and 12 months.  
 
CPAP 
The CPAP download data from the last study period is shown in table 5. The proportion 
of nights with 4 or more hours using CPAP data shows 19% of people used CPAP for 
60-100% of nights at 3 months, 27% at 6 months and 22% at 12 months.  
 
Blood tests 
There was no statistically significant change in HbA1c, cholesterol, HDL and 




This multi-centre UK randomised controlled trial of CPAP in patients with OSA and 
impaired vision due to DME and type 2 diabetes has shown no benefit to visual acuity 
from CPAP compared to standard ophthalmological care over a 12-month period. 
There was no statistically or clinically significant improvement with CPAP in the 
variables of vision, DME or retinal photography at any time point, nor change in other 
measures. There have been no other randomised controlled trials conducted in this 
area. This is therefore novel data, useful for clinical practice.  
 
OSA was found in 75% of people studied in the total cohort. Those people with 
symptomatic OSA with daytime sleepiness should be referred for CPAP to improve 
these symptoms.16 There has been increasing interest in whether CPAP can be used 
to treat conditions causally associated with OSA, such as hypertension, insulin 
resistance, type 2 diabetes, and cardiovascular disease.18,21,22,37 This is particularly 
relevant to those people with asymptomatic OSA, who do not require CPAP for 
daytime sleepiness, but in whom it might mitigate risk from another condition. The 
numbers of people with these comorbid conditions are enormous, so robust evidence 
to guide therapeutic decisions is essential. 
 
There was no additional benefit of CPAP for severe OSA for any ocular measure. The 
CPAP group had deterioration in CMT at three months which just reached statistical 
significance; it did not persist at six and 12 months. This was not associated with any 
significant difference in visual acuity between the two groups. This difference is not 
clinically significant; typically this would require an increase in CMT of ≥10% from 
baseline and a decrease in visual acuity of ≥5 letters.38 The CPAP group had a non-
significant higher average number of ocular interventions than the control group at 12 
months; perhaps these interventions occurred because of the CMT increase, and they 
were effective at correcting ongoing CMT differences between groups. It is not clear 
why the CPAP group would have increased CMT at 3 months compared to the control 
group; changes in ocular perfusion with CPAP are potentially plausible, causing an 
effect on ocular vascular permeability, but unlikely. No changes in CMT were found in 
the only other study of CPAP on DME.30 That smaller, uncontrolled study gave 32 
people with DME and OSA CPAP for six months. Post-randomisation division into high 
and low compliers showed those who used CPAP well (n=13, mean >2.5 hours/night) 
had significant improvements in visual acuity compared to those who were less 
compliant (n=15), with an adjusted treatment effect on VA of high adherence versus 
low adherence of 0.11 (95% confidence interval 0.21 to -0.002; p = 0.047), equivalent 
to a one-line improvement on LogMAR chart. There was no significant improvement 
in DME or retinal photographs, but interest in the potential benefit of CPAP to visual 
acuity led to this randomised controlled trial.   
 
In this trial, patients randomised to CPAP received additional support from sleep teams 
to optimise their adherence with this therapy. Despite this, the adherence to CPAP 
was lower than that seen in other trials of CPAP in individuals with OSA also found by 
screening specific non-sleep clinic populations: mean adherence in the SAVE study 
of people with coronary or cerebrovascular disease was 3.3 hours /night over several 
years, and it was 3.5 hours/night in a study of CPAP versus oxygen in OSA found in 
patients with cardiovascular disease, or known cardiovascular risk factors.22,39 The 
SAVE trial gave pre-randomisation subtherapeutic CPAP to ensure participants were 
adherent for an average of three hours per night; this excluded 324 people, or 10%, 
which no doubt improved trial CPAP adherence rates by excluding those who could 
not tolerate it at the outset. We felt a “real world” trial including all patients would be 
more applicable to clinical practice. All these studies prove that high adherence to 
CPAP in patients who have not presented to the sleep clinic with symptoms is difficult 
to achieve. It is known that CPAP use varies in patients in clinical practice. Possibly 
the patients in this study with type 2 diabetes, DME and other medical problems, but 
without sleepiness, found the additional burden of CPAP too much. The level of CPAP 
adherence may have been insufficient to affect visual outcomes, but there was no 
suggestion of any correlation of changes in visual acuity with CPAP use, nor any 
improvement seen in high compared to low CPAP users. A per protocol analysis was 
conducted for the primary outcome of LogMAR BCVA at 12 months, excluding the 
patients in the control arm who received CPAP (n=2) and those in the CPAP group 
who never used CPAP (n=5): it showed no difference to the results found in the 
intention to treat analysis (p=0.38). It therefore seems that although CPAP effectively 
treated OSA, confirmed by CPAP download data, it did not improve visual outcomes. 
CPAP may be unable to reverse established ocular damage in people who have 
diabetic macular oedema. Alternatively, best ophthalmic care (photocoagulation, 
antiVEGF, intravesical corticosteroids) may stabilise and improve vision, leaving no 
additional role for CPAP to reduce DME. Whether CPAP could be used as a potential 
tool for to prevent diabetic retinopathy, rather than reversing it, or delaying its 
progression, remains an area of interest and future studies are needed to ascertain 
whether CPAP has a valid role in this arena, particularly given the poor adherence in 
this group of patients. 
 
In this study, daytime sleepiness and quality of life, measured by the ESS and the 
SAQLI respectively, significantly improved in those with high CPAP compliance at 
three months. It is surprising this was not sustained throughout the trial and that there 
was no significant improvement in the SF-12 between groups. Both have been shown 
to improve in previous randomised controlled trials of CPAP.40 The lower median 
CPAP adherence than other studies of people with symptomatic OSA may be the 
reason; or the lack of therapeutic benefit may have tempered their use of CPAP. The 
participants in this study were screened for OSA, but had never sought previous help 
for OSA symptoms. Although the mean baseline ESS was within the normal range,  
other studies have shown that improvements in sleepiness occur regardless of the 
baseline ESS.21, 41 Whilst the prevalence of OSA was high in this cohort, these were 
not people who had presented with sleep symptoms, and therefore may have different 
treatment responses to those people with symptomatic OSA. At the end of the trial, 
63% of patients randomised to CPAP opted to continue, suggesting they had some 
form of symptomatic benefit from this.  
 
An observational prospective longitudinal study assessed 230 patients from diabetes 
clinics at two UK centres with assessments of DR via photography and OSA via home 
sleep studies 29. Sight threatening DR (STDR) prevalence was higher in patients with 
OSA than those without OSA (42.9% vs. 24.1%, p=0.004). After a median follow-up of 
43 months, patients with OSA were more likely to develop preproliferative/proliferative 
DR (18.4% vs. 6.1%; P=0.02). OSA remained an independent predictor of progression 
after adjustment for confounders (OR 5.2; 95% CI 1.2–23.0; P=0.03). All patients with 
moderate or severe OSA at baseline were referred for CPAP. High CPAP adherence 
significantly lowered progression to advanced DR and maculopathy (n=15). Whilst this 
study showed potential benefits from CPAP, it was in a small sub group of non-
randomised patients. The authors emphasised the need for a randomised control trial 
of CPAP. 
 
In conclusion, this is the only randomised controlled study to evaluate the effect of 
CPAP for OSA on visual acuity in people with macular oedema and type 2 diabetes. 
CPAP should continue to be given to patients with symptomatic OSA, but there is no 
evidence from this study to support its use as an alternative therapy for diabetic 
macular oedema when standard ophthalmic therapy is already being given.  
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Figure legends 
Figure 1. Screening, randomisation and follow up analyses 
Figure 2: Mean difference with 95% CIs of LogMAR at 3, 6 and 12 months  





Table 1: Baseline characteristics of the study participants   
Characteristics CPAP 
N (%) or Mean (SD) [Range] 
Control 
N (%) or Mean (SD) [Range] 
Gender                                       Male 43 (67.2) 52 (80.0) 
Female 21 (32.8) 13 (20.0) 
Age (years)  64.88 (10.44) [41.66 83.42] 64.19 (9.13) [39.03 81.10] 
BMI (kg/m2)  34.78 (8.74) [20.3 82.7] 35.23 (6.32) [22.0 50.5] 
Neck circumference (cm) 43.16 (4.09) [34.5 60.0] 44.81 (4.07) [36.0 54.0] 
Waist circumference (cm) 115.15 (11.99) [93 149.5] 118.59 (17.21) [67 151] 
Duration of diabetes (years) 15.91 (8.73) [1 37] 15.63 (9.47) [1 51] 
Epworth Sleepiness Score total  9.1 (5.9) [0 22] 9.0 (5.8) [0 24] 
Apnoea hypopnea index/hour 32.9 (16.9) [0 82] 33.7 (18.67) [0 107] 
Daytime oxygen saturations on air 
at rest (%) 
96.4 (1.9) [89 100] 96.5 (1.6) [91 99] 
Oxygen desaturation index  36.5 (17.9) [20 99] 36.3 (15.6) [20 84] 
SAQLI score total 3.0 (1.4) [1.1 5.7] 3.1 (1.4) [1.0 6.3] 
SF12 score total   
Physical Health Composite score 38.6 (6.5) [24.2 53.2] 38.7 (6.4) [25.3 49.7] 
Mental Health Composite score 50.2 (8.2) [29.9 67.8] 50.4 (7.6) [29.4 62.1] 
VFQ 25 score total 70.0 (19.9) [28.0 98.2] 75.3 (19.4)  [18.9 98.5] 
Total cholesterol (mmol/L)  4.27 (1.09) [2.4 7.1] 4.09 (1.08) [2.2 7.4] 
HDL (mmol/L)  1.18 (0.36) [0.6 2.3] 1.20 (0.36) [0.6 2.03] 
Triglycerides (mmol/L) 2.08 (1.08) [0.7 5.5] 2.08 (1.41) [0.6 7.3] 
TSH (mU/L) 2.5 (1.5) [0.7 7.5] 2.0 (1.2) [0.4 6.6] 
T4 (Pmol/L) 14.8 (2.3) [10 19] 14.7 (2.2) [9.3 19.2] 
HbA1C (mmol/mol) 66.9 (17.6) [40 127] 66.0 (23.3) [13.4 163] 
LogMAR BCVA 0.36 (0.21) [-0.08 1.08] 0.35 (0.22) [-0.18 0.9] 
Central Macular Thickness (CMT) 364.3 (107.9) [173 742] 346.3 (102.6) [119 671] 
Retinopathy                                       1      36 (59) 33 (54) 
2 18 (30) 21 (34) 
3 7 (11) 7 (12) 
Maculopathy                                     0 17 (28) 28 (46) 
1 44 (72) 33 (54) 
Photocoagulation                              0 31 (51) 27 (44) 
1 30 (49) 34 (56) 
BMI = body mass index, ODI =4% oxygen desturation index per hour, SAQLI = sleep apnoea 
quality of life index, SF12= short form 12, VFQ-25 = visual function questionnaire, TSH = 
thyroid stimulating hormone, HDL = high density lipoprotein 
 
Table 2. Results of LogMAR at 3, 6, and 12 months  
Month N CPAP 
Mean* (95% CI) 
N Control 




3 Months 59 0.34 (0.31 to 0.38) 60 0.30 (0.27 to 0.34) 0.04 (-0.01 to 0.09) 0.113 
6 Months 60 0.33 (0.30 to 0.37) 60 0.30 (0.26 to 0.33) 0.03 (-0.02 to 0.09) 0.217 
12 Months 57 0.33 (0.29 to 0.37) 60 0.31 (0.27 to 0.35) 0.03 (-0.03 to 0.08) 0.390 




Table 3: Progression of Diabetic Retinopathy at 12 Months 





Retinopathy 1 32/53 (60) 31/54 (57) 0.825 
2 13/53 (25) 16/54 (30) 
3 8/53 (15) 7/54 (13) 
Maculopathy 0 22/53 (42) 25/54 (46) 0.618 
1 31/53 (58) 29/54 (54) 
Photocoagulation 0 22/53 (42) 20/54 (37) 0.636 
1 31/53 (58) 34/54 (63) 
* From Pearson’s Chi-Squared test 
  
Table 4: Epworth Sleepiness Score  
Month N CPAP 
Mean* (95% CI) 
N Control 




3 Months 59 7.7 (6.8, 8.7) 60 8.0 (7.2, 8.9) -0.3 (-1.6, 1.0) 0.633 
6 Months 59 6.7 (5.7, 7.7) 60 7.6 (6.7, 8.5) -0.9 (-2.2, 0.5) 0.210 
12 Months 57 7.2 (6.1, 8.3) 60 7.6 (6.7, 8.5) -0.4 (-1.9, 1.1) 0.587 
*calculated from linear mixed model adjusting for the baseline ESS score and minimisation factors. 
 
Table 5: CPAP usage at 3, 6 and 12 months 
 3 months 6 months 12 months 
N Mean (SD) [Range] N Mean (SD) [Range] N Mean (SD) [Range] 
Pressure 95th centile 
(cm/H2O) 
57 10.9 (3.6) [4, 19.3] 48 11.6 (3.6) [4.6, 19.2] 42 11.5 (3.6) [4.0, 18.2] 
Apnoea-hypopnoea 
index/hour 
57 1.9 (2.7) [0, 10] 48 1.9 (2.5) [0, 11.8] 42 1.7 (2.3) [0, 8.4] 
Obstructive events/hour 57 0.78 (1.44) [0, 8.3] 48 0.65 (1.11) [0, 6.2] 42 0.54 (0.79) [0, 3.1] 
Central events /hour 57 0.84 (1.66) [0, 8.5] 48 0.75 91.34) [0, 6.2] 42 0.70 (1.37) [0, 6.5] 
Median daily usage (hours) 57 3.33 (2.25) [0, 7.93] 57 3.19 (2.54) [0, 8.07] 57 3.21 (2.70) [0, 7.98] 
Average daily usage 
(hours) 
57 2.35 (2.09) [0, 7.48] 57 2.16 (2.30) [0, 6.9] 57 1.78 (2.18) [0, 6.53] 
 
  
























































-Case notes review (n=17) 
-Symptomatic driver (n=3) 
-Patient declined (n=23) 
-Died before baseline (n=2) 
-Respiratory failure (n=1) 
-Central sleep apnoea likely (n=7) 
Baseline visit 
n=171 Excluded (n=40) 
-Visual acuity too good (n=26) 
-Visual acuity too poor (n=2) 
-No macular oedema (n=7) 
-Other Ophthalmology (n=2) 
-Declined during baseline (n=2) 
-Other (DM1) (n=1) 
Discontinued the study (n=7) 
-Withdrawn (n=6) 
-Died (n=1)  
Discontinued the study  (n=5) 
-Withdrawn (n=2) 
-Died (n=1)  
-Lost to f-up (n=2) 




No sleep study sent   (n=66) 
excluded on Hx review       (n=30) 
declined                   (n= 9) 
unable to contact                (n=27) 
Study not completed    (n= 124) 
declined                  (n= 63) 
difficulty using                     (n= 39) 
inability to deliver/return  (n= 22) 
Completed 12 months follow-up 
n=57 
Analysed at 12 months (n=57)  
Completed 12 months follow-up 
n=60 
Analysed at 12 months (n=60)  
Sleep study completed 
n=686 
Excluded on ODI (n=462) 
-ODI <5 (n=161) 
-ODI 5-14 (n=249) 
-ODI 15-19 (n=36) 
-No ODI (AHI review) (n=16) 
Excluded from trial (n=2) 
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